相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Luciano J. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance
Mahmoud R. Gaballa et al.
LEUKEMIA & LYMPHOMA (2022)
Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost
Kevin Y. Chen et al.
TRANSFUSION AND APHERESIS SCIENCE (2022)
Knowing the unknowns in high risk multiple myeloma
Benjamin A. Derman et al.
BLOOD REVIEWS (2022)
Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient
Vadlamani Surya Prakash et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
Ibai Goicoechea et al.
BLOOD (2021)
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
Nico Gagelmann et al.
BONE MARROW TRANSPLANTATION (2021)
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Hartmut Goldschmidt et al.
LEUKEMIA (2021)
Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial
Hartmut Goldschmidt et al.
BLOOD (2021)
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI plus Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial
Martin F. Kaiser et al.
BLOOD (2021)
Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial
Noemi Puig et al.
BLOOD (2021)
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD ResponseAdapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial
Luciano J. Costa et al.
BLOOD (2021)
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Jonathan L. Kaufman et al.
BLOOD (2021)
Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)
Aurore Perrot et al.
BLOOD (2021)
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
Larry D. Anderson et al.
BLOOD (2021)
Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation AntigenDirected Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
Thomas Martin et al.
BLOOD (2021)
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Hartmut Goldschmidt et al.
BLOOD (2021)
Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Laura Rosinol et al.
BLOOD (2021)
Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
Herve Avet Loiseau et al.
BLOOD (2021)
OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)
Rakesh Popat et al.
Clinical Lymphoma Myeloma & Leukemia (2021)
OAB-004: Carfilzomib-based induction/consolidation with or without autologous transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) maintenance: efficacy in high-risk patients of the FORTE study
Roberto Mina et al.
Clinical Lymphoma Myeloma & Leukemia (2021)
OAB-015: Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk
Ruth De Tute et al.
Clinical Lymphoma Myeloma & Leukemia (2021)
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Marc-Andrea Baertsch et al.
BLOOD CANCER JOURNAL (2021)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. A. Dimopoulos et al.
ANNALS OF ONCOLOGY (2021)
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Francesca Gay et al.
LANCET ONCOLOGY (2021)
Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry
Mohamed-Amine Bekadja et al.
CYTOTHERAPY (2021)
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results
Murielle Roussel et al.
BLOOD (2021)
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial
Ola Landgren et al.
JAMA ONCOLOGY (2021)
Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).
Kwee Yong et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Philippe Moreau et al.
LANCET ONCOLOGY (2021)
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods
Jill Corre et al.
LEUKEMIA (2021)
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
Stefania Oliva et al.
BLOOD CANCER JOURNAL (2021)
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Benjamin Diamond et al.
Lancet Haematology (2021)
Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation-A Blood or Marrow Transplant Survivor Study Report
Smith Giri et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience
Iuliana Vaxman et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Hartmut Goldschmidt et al.
LEUKEMIA (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
Nisha S. Joseph et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).
Parameswaran Hari et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis
D. Laszlo et al.
TRANSFUSION AND APHERESIS SCIENCE (2020)
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
Brian G. M. Durie et al.
BLOOD CANCER JOURNAL (2020)
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jagoda K. Jasielec et al.
BLOOD (2020)
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo et al.
LANCET HAEMATOLOGY (2020)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Defining and Managing High-Risk Multiple Myeloma: Current Concepts
Luciano J. Costa et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
Paola Tacchetti et al.
Lancet Haematology (2020)
High-risk myeloma: a challenge to define and to determine the optimal treatment
Charlotte Pawlyn
Lancet Haematology (2020)
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
Saad Z Usmani et al.
Lancet Haematology (2020)
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Nikhil C. Munshi et al.
BLOOD ADVANCES (2020)
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Followup Analysis of the IFM 2009 Trial
Aurore Perrot et al.
BLOOD (2020)
Fresh Versus Cryopreserved Peripheral Stem Cell for Autologous Transplantation in Multiple Myeloma: An Analysis of Short-Term Outcomes
Jacinth Joseph et al.
BLOOD (2020)
Long-term outcomes after autologous stem cell transplantation for multiple myeloma
Katherine K. Nishimura et al.
BLOOD ADVANCES (2020)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
Edward A. Stadtmauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos et al.
LANCET (2019)
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H. Jackson et al.
LANCET ONCOLOGY (2019)
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial
H. Goldschmidt et al.
LEUKEMIA (2018)
Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma
Rahul Naithani et al.
BONE MARROW TRANSPLANTATION (2018)
Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy
M. Sarmiento et al.
BONE MARROW TRANSPLANTATION (2018)
Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas
Amado Kardduss-Urueta et al.
BONE MARROW TRANSPLANTATION (2018)
Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant
Uday Kulkarni et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib plus Lenalidomide plus Dexamethasone or Bortezomib plus Thalidomide plus Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Laura Rosinol Dachs et al.
BLOOD (2018)
Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents
Helgi van de Velde et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
Sarah A. Holstein et al.
LANCET HAEMATOLOGY (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau et al.
BLOOD (2016)
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook et al.
LANCET HAEMATOLOGY (2016)
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay et al.
LANCET ONCOLOGY (2015)
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
Sergio Giralt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma: A Single Institution Experience at All India Institute of Medical Sciences, New Delhi, Using Non-Cryopreserved Peripheral Blood Stem Cells
Smita Kayal et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma
Heinz Ludwig et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
An automatic wash method for dimethyl sulfoxide removal in autologous hematopoietic stem cell transplantation decreases the adverse effects related to infusion
Andres Sanchez-Salinas et al.
TRANSFUSION (2012)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Recent major improvement in long-term survival of younger patients with multiple myeloma
Hermann Brenner et al.
BLOOD (2008)
Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review
L. Wannesson et al.
ANNALS OF ONCOLOGY (2007)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the group myelome-autogreffe
J Fermand et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
J Bladé et al.
BLOOD (2005)
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
A Palumbo et al.
BLOOD (2004)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)